07 December 2023
07 December 2023
Dr Christina Yap and her team developed the SPIRIT and CONSORT guidance to assist researchers write papers on Phase I clinical trials.
Tukysa in combination with Kadcyla met the primary endpoint of increasing progression-free survival in patients with HER2-positive breast cancer.
The company plans to conduct several trials with its drug-device combo in schizophrenia and opioid use disorder over the next couple of years.
In the trial, tamibarotene combination treatment offered a 100% CR/CRi rate in evaluable patients versus 70% in the control arm.
Overall survival is the primary endpoint of the trial analysing imetelstat versus best available therapy.
The collaboration focuses on the evaluation of real-world data study designs and methods for informing regulatory objectives.
Apart from injection site irritation, no notable side effects were reported in the trial.
The placebo-controlled and randomised study is anticipated to enrol around 60 patients with active RA.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
